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Percutaneous
Revascularization of Chronic
Total Coronary Occlusions
Are the Benefits Underappreciated?*
Jeffrey W. Moses, MD,† Dimitri Karmpaliotis, MD‡
New York, New York; and Atlanta, Georgia
Chronically totally occluded coronary arteries (CTOs) are
common and represent the most technically challenging
subset of lesions in contemporary interventional cardiology
(1). The presence of a CTO on coronary angiography has a
powerful impact on treatment decisions, leading to more
frequent referral to coronary artery bypass grafting (CABG)
and medical therapy when compared with when only
stenotic lesions are present.
See page 380
In carefully selected patients, successful percutaneous
CTO revascularization leads to a meaningful reduction in
symptoms (2–7), improved left ventricular function (8), and
a reduction in the need for subsequent CABG (9). In
addition, a mounting number of registry studies (5–7,9–20)
(Table 1) demonstrate, with a few exceptions, that success-
ful CTO revascularization is associated with improved
survival (9,18) particularly in the setting of multivessel
disease when complete revascularization is achieved (4).
In this issue of JACC: Cardiovascular Interventions, Jones
t al. (19) report their single-center experience with long-
erm survival in patients with chronic stable angina who had
ndergone attempted percutaneous CTO revascularization.
atients (n  836) who underwent CTO percutaneous
oronary intervention (PCI) between 2003 and 2010 were
ollowed for up to 5 years (median of 3.8 years). They
chieved approximately a 70% acute success rate, with low
n-hospital major adverse cardiac events (2.1% in successful
ases, and 3.1% in failures). The authors were able to
*Editorials published in the JACC: Cardiovascular Interventions reflect the views of the
authors and do not necessarily represent the views of JACC: Cardiovascular Interven-
tions or the American College of Cardiology.
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and as consultant for BridgePoint Medical—each for modest compensation.apture all deaths through the U.K. Office of National
tatistics. Procedural success compared with failure was
ssociated with improved all-cause mortality at 5 years of
ollow-up (4.5% vs. 17.2%, p  0.0001), a survival on par
ith non-CTO PCI (6.7%). Drug-eluting stent use (76.1%
f cases) was associated with a trend toward improved
ortality when compared with patients treated with bare-
etal stents. Furthermore, after regression analysis proce-
ural success remained a powerful independent predictor of
urvival (hazard ratio: 0.28, 95% confidence interval: 0.15 to
.52). In addition subsequent target vessel revascularization
CABG and PCI) was significantly lower for patients with
uccessful CTO PCI versus those with unsuccessful CTO
CI (11.5% vs. 22.1%, p  0.0001). Previous PCI and
ABG were more frequent in the unsuccessful group, but
therwise the reported clinical and demographic character-
stics were well matched between the 2 groups.
Despite the acknowledged limitations of selection bias
mpacting both the initial treatment selection as well as
ubsequent treatment after unsuccessful CTO PCI, inher-
nt to all observational registry studies, the rigorous
ollow-up in this report is a welcome addition to the existing
ata indicating that CTO revascularization improves sur-
ival (Table 1). However, one must be mindful that all
egistry data are subject to potential confounders, for exam-
le: 1) complications related to CTO PCI failure can lead to
eath (20) (unlikely in this report, given the low in-hospital
ajor adverse cardiac events); 2) PCI failure can be a marker
f disease burden and other comorbidities such as frailty and
hronic kidney disease; and 3) other diseases that shorten
ifespan might limit the vigor of the CTO attempt. A more
etailed understanding of the differences in causes of death
n the Jones et al. report (19) could have lent more insight
o this important issue.
It is of interest that Jones et al. (19) demonstrated this
urvival benefit in a population predominantly comprising
atients with single-vessel disease (SVD) with the majority
f the treated vessels involving the right coronary artery.
he Kaplan-Meier curves diverge early and continue to
iverge throughout the duration of the study, which is
imilar to other recent reports (18). Other studies suggesting
urvival impact include the presence of left anterior de-
cending coronary artery CTO in SVD (21) or the presence
f a CTO in post-myocardial infarction (MI) patients (22).
The possible mechanisms of survival benefit after success-
ul CTO revascularization are not fully understood. How-
ver, several possibilities can be considered: 1) reduction in
uture arrhythmic events (23); 2) improvement in left
entricular function (8); 3) reduction in ischemic burden
24); 4) potentially better tolerance of future MIs in a
on-CTO artery (22); 5) less referral to CABG (9); and
) reduced incidence of future acute coronary syndromes,
lthough in 2 large recent reports, there were differences in
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390subsequent MI during the follow-up period between these
subgroups (9,18).
The fact that the presence of a CTO is one of the major
anatomic predictors for referral to CABG leads one to
conclude that a large majority of cardiologists believe CTOs
should be revascularized. However, in the SYNTAX (Syn-
ergy between PCI with Taxus and Cardiac Surgery) trial,
approximately one-third of the CTOs referred for CABG
were not surgically revascularized (25). Thus it should not
be taken for granted that full revascularization will occur
simply by referring a patient with CTO for CABG.
Three main arguments against CTO PCI include: 1) the
negative results of the OAT (Occluded Artery Trial) (26);
2) the assumption that well-developed collaterals supplying
the CTO territory provide adequate blood flow to the
myocardium at risk under situations of increased oxygen
demand; and 3) the lack of a randomized trial that would
definitively address the question of whether successful CTO
PCI improves survival.
In the first instance, OAT was by design a non-CTO trial
(26), because the mean period from MI to randomization
was 8 days, whereas by definition chronicity is defined by
its presence for a minimum of 3 months. A closer look at
the population in OAT reveals that the vast majority of the
patients (83%) had either mild or no symptoms and, of the
27% who had a functional ischemic assessment (the balance
were presumed to have “completed” infarcts), 90% had either
mild or no ischemia. In addition, with 82% of the patients
having SVD (50% right coronary artery), it is no surprise that
there was no survival benefit. On the second point, Werner et
Table 1. Effect of Successful Versus Failed CTO PC
First Author, Year (Ref. #) Follow-Up (yrs)
Finci et al., 1990 (5) 2
Warren et al., 1990 (10) 2.6
Ivanhoe et al., 1992 (6) 4
Angioi et al., 1995 (11) 3.6
Noguchi et al., 2000 (12) 4.3
Suero et al., 2001 (13) 10
Olivari et al., 2003 (7) 1
Hoye et al., 2005 (14) 4.5
Drozd et al., 2006 (15) 2.5
Aziz et al., 2007 (16) 1.7
Prasad et al., 2007 (17) 10
Valenti et al., 2008 (4) 1
de Labriolle et al., 2008 (20) 2
Mehran et al., 2011 (18) 2.9
Jones et al., 2012 (19) 3.8
Joyal et al., 2010* (9)
Successful PCI is associated with large reductions in the risk (OR) of d
CI confidence interval(s); CTO chronically totally occluded cor
PCI percutaneous coronary intervention.al. (27), in an elegant study, assessed the collateral fractionalflow reserve in 62 patients with CTOs, after successful wire
crossing. This study found not a single patient with a collateral
fractional flow reserve 0.80 (the current accepted ischemic
threshold), suggesting that although collaterals might be ade-
quate for preservation of myocardial viability, they rarely
prevent stress-induced ischemia. This of course leads to the
paradox that, under current appropriate use criteria, PCI is
appropriate for a 99% proximal left anterior descending coro-
nary artery but not for 100% (28).
Several recent publications have shown that with contem-
porary techniques consistently high success rates can be
achieved with acceptable rate of complications in very
complex lesions (29,30). So there is good news: we have the
right setting for a U.S.-based randomized trial. But design-
ing such a trial raises many issues. Chronically totally
occluded coronary arteries occur in a variety of scenarios:
SVD, multivessel disease, associated with different degrees
of ischemic burden, in patients with chronic stable angina,
asymptomatic patients with abnormal function studies, and
acute coronary syndromes. Which patient population do we
need to focus on? Are mortality and/or MI the only primary
endpoints of significance? Are there really enough expert
centers that could participate in the trial and complete it in
a reasonable time period? Who would fund such an expensive
trial?
The Euro CTO Group and a group from Korea (Deci-
sion CTO) are currently randomizing patients with chronic
stable angina to PCI versus medical therapy with combined
primary endpoint of mortality, MI, stroke, and revascular-
ization at 36 months. The investigators should be com-
l-Cause Mortality During Long-Term Follow-Up
ccess (n) PCI Failure (n) OR/HR, 95% CI
100 100 OR: 1.70, 0.40–7.32
26 18 N/A
317 163 OR: 0.21, 0.05–0.83
93 108 OR: 0.37, 0.10–1.40
134 92 OR: 0.28, 0.11–0.72
,491 514 OR: 0.67, 0.54–0.83
289 87 OR: 0.19, 0.03–1.14
567 304 OR: 0.52, 0.32–0.84
298 161 OR: 0.74, 0.23–2.37
377 166 OR: 0.31, 0.13–0.76
914 348 OR: 0.82, 0.62–1.08
344 142 OR: 0.38, 0.19–0.77
127 45 OR: 1.25, 0.25–6.27
,226 565 HR: 0.63, 0.40–1.0
582 254 HR: 0.28, 0.15–0.52
,056 2236 OR: 0.56, 0.43–0.72
er several years. *Meta-analysis including 13 studies (4–7,20,25–32).
rtery; HR hazard ratio; N/A not applicable; OR odds ratio(s);I in Al
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391are highly anticipated, and the progress of the trial will be
very informative with regard to the feasibility of a similar
U.S.-based trial. Even in the best-case scenario the results
from these trials are not expected before 2018.
How should patients with CTOs be treated until then?
On the basis of the available evidence, it is reasonable to
revascularize symptomatic CTOs, CTOs associated with
significant ischemic burden (10% of myocardium at risk),
and CTOs in the setting of multivessel disease to achieve
complete revascularization and to improve left ventricular
function.
In summary, when confronted with a CTO, given the
current body of knowledge, should not the patient be given
the benefit of the doubt? Unfortunately, in the contempo-
rary environment of searching for definitive evidence of cost
effectiveness before recommending a procedure, weighing
the odds of benefit from the perspective of the patient is not
in vogue. A fair and complete presentation of the state of
the art can empower patients and allow them a stronger
voice in the decision-making process.
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